{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:34:50Z","timestamp":1794569690277,"version":"4.9.1"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017618","name":"Division of Diabetes, Endocrinology, and Metabolic Diseases","doi-asserted-by":"publisher","award":["R01DK111038"],"award-info":[{"award-number":["R01DK111038"]}],"id":[{"id":"10.13039\/100017618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000901","name":"Juvenile Diabetes Research Foundation International","doi-asserted-by":"publisher","award":["3-SRA-2022-1186-S-B"],"award-info":[{"award-number":["3-SRA-2022-1186-S-B"]}],"id":[{"id":"10.13039\/100000901","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clinically symptomatic type 1 diabetes (stage 3 type 1 diabetes) is preceded by a pre-symptomatic phase, characterised by progressive loss of functional beta cell mass after the onset of islet autoimmunity, with (stage 2) or without (stage 1) measurable changes in glucose profile during an OGTT. Identifying metabolic tests that can longitudinally track changes in beta cell function is of pivotal importance to track disease progression and measure the effect of disease-modifying interventions. In this review we describe the metabolic changes that occur in the early pre-symptomatic stages of type 1 diabetes with respect to both insulin secretion and insulin sensitivity, as well as the measurable outcomes that can be derived from the available tests. We also discuss the use of metabolic modelling to identify insulin secretion and sensitivity, and the measurable changes during dynamic tests such as the OGTT. Finally, we review the role of risk indices and minimally invasive measures such as those derived from the use of continuous glucose monitoring.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s00125-023-06011-5","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T06:01:45Z","timestamp":1694757705000},"page":"2189-2199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Quantifying beta cell function in the preclinical stages of type 1 diabetes"],"prefix":"10.1007","volume":"66","author":[{"given":"Alfonso","family":"Galderisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice L. J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Senior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"issue":"10","key":"6011_CR1","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","volume":"38","author":"R Insel","year":"2015","unstructured":"Insel R, Dunne J, Atkinson M et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38(10):1964\u201374. https:\/\/doi.org\/10.2337\/dc15-1419","journal-title":"Diabetes Care"},{"issue":"8","key":"6011_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM198508223130801","volume":"313","author":"S Srikanta","year":"1985","unstructured":"Srikanta S, Ganda O, Rabizadeh A, Soeldner J, Eisenbarth G (1985) First-degree relatives of patients with type I diabetes mellitus. Islet-cell antibodies and abnormal insulin secretion. N Engl J Med 313(8):461\u20134. https:\/\/doi.org\/10.1056\/NEJM198508223130801","journal-title":"N Engl J Med"},{"issue":"15","key":"6011_CR3","doi-asserted-by":"publisher","first-page":"e120877","DOI":"10.1172\/jci.insight.120877","volume":"3","author":"C Evans-Molina","year":"2018","unstructured":"Evans-Molina C, Sims E, DiMeglio L et al (2018) \u03b2 Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis. JCI insight 3(15):e120877. https:\/\/doi.org\/10.1172\/jci.insight.120877","journal-title":"JCI insight"},{"key":"6011_CR4","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab344","author":"A Galderisi","year":"2021","unstructured":"Galderisi A, Moran A, Evans-Molina C et al (2021) Early impairment of insulin sensitivity, \u03b2-cell responsiveness, and insulin clearance in youth with stage 1 type 1 diabetes. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgab344","journal-title":"J Clin Endocrinol Metab"},{"key":"6011_CR5","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2337\/db09-1378","volume":"59","author":"E Ferrannini","year":"2010","unstructured":"Ferrannini E, Mari A, Nofrate V, Sosenko JM, Skyler JS (2010) Progression to diabetes in relatives of type 1 diabetic patients: mechanisms and mode of onset. Diabetes 59:679\u2013685. https:\/\/doi.org\/10.2337\/db09-1378","journal-title":"Diabetes"},{"issue":"3","key":"6011_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s00125-022-05836-w","volume":"66","author":"E Ferrannini","year":"2023","unstructured":"Ferrannini E, Mari A, Monaco G, Skyler J, Evans-Molina C (2023) The effect of age on longitudinal measures of beta cell function and insulin sensitivity during the progression of early stage type 1 diabetes. Diabetologia 66(3):508\u2013519. https:\/\/doi.org\/10.1007\/s00125-022-05836-w","journal-title":"Diabetologia"},{"issue":"2","key":"6011_CR7","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S2213-8587(22)00390-4","volume":"11","author":"C Evans-Molina","year":"2023","unstructured":"Evans-Molina C, Orma R (2023) Teplizumab approval for type 1 diabetes in the USA. Lancet Diabetes Endocrinol 11(2):76\u201377. https:\/\/doi.org\/10.1016\/S2213-8587(22)00390-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"583","key":"6011_CR8","doi-asserted-by":"publisher","first-page":"eabc8980","DOI":"10.1126\/scitranslmed.abc8980","volume":"13","author":"E Sims","year":"2021","unstructured":"Sims E, Bundy B, Stier K et al (2021) Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med 13(583):eabc8980. https:\/\/doi.org\/10.1126\/scitranslmed.abc8980","journal-title":"Sci Transl Med"},{"issue":"7","key":"6011_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","volume":"381","author":"K Herold","year":"2019","unstructured":"Herold K, Bundy B, Long S et al (2019) An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med 381(7):603\u2013613. https:\/\/doi.org\/10.1056\/NEJMoa1902226","journal-title":"N Engl J Med"},{"issue":"1","key":"6011_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/bmb\/ldab027","volume":"140","author":"L Allen","year":"2021","unstructured":"Allen L, Dayan C (2021) Immunotherapy for type 1 diabetes. Br Med Bull 140(1):76\u201390. https:\/\/doi.org\/10.1093\/bmb\/ldab027","journal-title":"Br Med Bull"},{"issue":"Suppl. 1","key":"6011_CR11","doi-asserted-by":"publisher","first-page":"S212","DOI":"10.2337\/diabetes.51.2007.s212","volume":"51","author":"RN Bergman","year":"2002","unstructured":"Bergman RN, Ader M, Huecking K, Van Citters G (2002) Accurate assessment of beta-cell function: the hyperbolic correction. Diabetes 51(Suppl. 1):S212-220. https:\/\/doi.org\/10.2337\/diabetes.51.2007.s212","journal-title":"Diabetes"},{"issue":"11","key":"6011_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2337\/diab.42.11.1663","volume":"42","author":"SE Kahn","year":"1993","unstructured":"Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42(11):1663\u20131672. https:\/\/doi.org\/10.2337\/diab.42.11.1663","journal-title":"Diabetes"},{"issue":"6","key":"6011_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/s0022-3476(89)80438-x","volume":"114","author":"S Caprio","year":"1989","unstructured":"Caprio S, Plewe G, Diamond MP et al (1989) Increased insulin secretion in puberty: a compensatory response to reductions in insulin sensitivity. J Pediatr 114(6):963\u2013967. https:\/\/doi.org\/10.1016\/s0022-3476(89)80438-x","journal-title":"J Pediatr"},{"key":"6011_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMoa012350","volume":"346","author":"Diabetes Prevention Trial \u2013 Type 1 Diabetes Study Group","year":"2002","unstructured":"Diabetes Prevention Trial \u2013 Type 1 Diabetes Study Group (2002) Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 346:1685\u20131691. https:\/\/doi.org\/10.1056\/NEJMoa012350","journal-title":"N Engl J Med"},{"issue":"4","key":"6011_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MED.0000000000000548","volume":"27","author":"E Sims","year":"2020","unstructured":"Sims E, Mirmira R, Evans-Molina C (2020) The role of beta-cell dysfunction in early type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 27(4):215\u2013224. https:\/\/doi.org\/10.1097\/MED.0000000000000548","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"12","key":"6011_CR16","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.2337\/db13-0656","volume":"62","author":"J Sosenko","year":"2013","unstructured":"Sosenko J, Skyler J, Beam C et al (2013) Acceleration of the loss of the first-phase insulin response during the progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes 62(12):4179\u20134183. https:\/\/doi.org\/10.2337\/db13-0656","journal-title":"Diabetes"},{"issue":"8","key":"6011_CR17","doi-asserted-by":"publisher","first-page":"e3273","DOI":"10.1210\/clinem\/dgac285","volume":"107","author":"D Baidal","year":"2022","unstructured":"Baidal D, Warnock M, Xu P et al (2022) Oral glucose tolerance test measures of first-phase insulin response and their predictive ability for type 1 diabetes. J Clin Endocrinol Metab 107(8):e3273\u2013e3280. https:\/\/doi.org\/10.1210\/clinem\/dgac285","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"6011_CR18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1210\/clinem\/dgac740","volume":"108","author":"A Galderisi","year":"2022","unstructured":"Galderisi A, Evans-Molina C, Martino M, Caprio S, Cobelli C, Moran A (2022) Beta cell function and insulin sensitivity in youth with early type 1 diabetes from a two-hour 7-sample OGTT. J Clin Endocrinol Metab 108(6):1376\u20131386. https:\/\/doi.org\/10.1210\/clinem\/dgac740","journal-title":"J Clin Endocrinol Metab"},{"key":"6011_CR19","doi-asserted-by":"publisher","first-page":"154870","DOI":"10.1016\/j.metabol.2021.154870","volume":"124","author":"GC Weir","year":"2021","unstructured":"Weir GC, Butler PC, Bonner-Weir S (2021) The \u03b2-cell glucose toxicity hypothesis: attractive but difficult to prove. Metabolism 124:154870. https:\/\/doi.org\/10.1016\/j.metabol.2021.154870","journal-title":"Metabolism"},{"issue":"12","key":"6011_CR20","doi-asserted-by":"publisher","first-page":"e146788","DOI":"10.1172\/JCI146788","volume":"131","author":"T Mezza","year":"2021","unstructured":"Mezza T, Ferraro PM, Di Giuseppe G et al (2021) Pancreaticoduodenectomy model demonstrates a fundamental role of dysfunctional \u03b2 cells in predicting diabetes. J Clin Invest 131(12):e146788. https:\/\/doi.org\/10.1172\/JCI146788","journal-title":"J Clin Invest"},{"issue":"12","key":"6011_CR21","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00125-002-0981-8","volume":"45","author":"P Keskinen","year":"2002","unstructured":"Keskinen P, Korhonen S, Kupila A et al (2002) First-phase insulin response in young healthy children at genetic and immunological risk for type I diabetes. Diabetologia 45(12):1639\u201348. https:\/\/doi.org\/10.1007\/s00125-002-0981-8","journal-title":"Diabetologia"},{"issue":"1","key":"6011_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.2337\/db19-0329","volume":"69","author":"M Koskinen","year":"2020","unstructured":"Koskinen M, Mikk M, Laine A et al (2020) Longitudinal pattern of first-phase insulin response is associated with genetic variants outside the class iI HLA region in children with multiple autoantibodies. Diabetes 69(1):12\u201319. https:\/\/doi.org\/10.2337\/db19-0329","journal-title":"Diabetes"},{"issue":"5","key":"6011_CR23","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s00125-006-0160-4","volume":"49","author":"P Bingley","year":"2006","unstructured":"European Nicotinamide Diabetes Intervention Trial (ENDIT) Group, Bingley P, Gale E (2006) Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia 49(5):881\u201390. https:\/\/doi.org\/10.1007\/s00125-006-0160-4","journal-title":"Diabetologia"},{"issue":"10","key":"6011_CR24","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.1109\/TBME.2011.2164918","volume":"58","author":"MG Pedersen","year":"2011","unstructured":"Pedersen MG, Dalla Man C, Cobelli C (2011) Multiscale modeling of insulin secretion. IEEE Trans Biomed Eng 58(10):3020\u20133. https:\/\/doi.org\/10.1109\/TBME.2011.2164918","journal-title":"IEEE Trans Biomed Eng"},{"issue":"12","key":"6011_CR25","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1172\/JCI106197","volume":"48","author":"D Porte","year":"1969","unstructured":"Porte D, Pupo A (1969) Insulin responses to glucose: evidence for a two pool system in man. J Clin Investig 48(12):2309\u201319. https:\/\/doi.org\/10.1172\/JCI106197","journal-title":"J Clin Investig"},{"issue":"3","key":"6011_CR26","doi-asserted-by":"publisher","first-page":"620","DOI":"10.2337\/dc09-1770","volume":"33","author":"J Sosenko","year":"2010","unstructured":"Sosenko J, Palmer J, Rafkin L et al (2010) Trends of earlier and later responses of C-peptide to oral glucose challenges with progression to type 1 diabetes in diabetes prevention trial-type 1 participants. Diabetes Care 33(3):620\u2013625. https:\/\/doi.org\/10.2337\/dc09-1770","journal-title":"Diabetes Care"},{"issue":"8","key":"6011_CR27","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.2337\/dc19-2288","volume":"43","author":"M Bogun","year":"2020","unstructured":"Bogun M, Bundy B, Goland R, Greenbaum C (2020) C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet. Diabetes Care 43(8):1836\u20131842. https:\/\/doi.org\/10.2337\/dc19-2288","journal-title":"Diabetes Care"},{"issue":"10","key":"6011_CR28","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.2337\/dc22-0167","volume":"45","author":"H Ismail","year":"2022","unstructured":"Ismail H, Cuthbertson D, Gitelman S et al (2022) The transition from a compensatory increase to a decrease in C-peptide during the progression to type 1 diabetes and its relation to risk. Diabetes Care 45(10):2264\u20132270. https:\/\/doi.org\/10.2337\/dc22-0167","journal-title":"Diabetes Care"},{"issue":"10","key":"6011_CR29","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.2337\/dc21-0226","volume":"44","author":"M Voss","year":"2021","unstructured":"Voss M, Cuthbertson D, Cleves M et al (2021) Time to peak glucose and peak C-peptide during the progression to type 1 diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. Diabetes Care 44(10):2329\u20132336. https:\/\/doi.org\/10.2337\/dc21-0226","journal-title":"Diabetes Care"},{"issue":"11","key":"6011_CR30","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.2337\/dc20-0701","volume":"43","author":"H Ismail","year":"2020","unstructured":"Ismail H, Cleves M, Xu P et al (2020) The pathological evolution of glucose response curves during the progression to type 1 diabetes in the TrialNet Pathway to Prevention Study. Diabetes Care 43(11):2668\u20132674. https:\/\/doi.org\/10.2337\/dc20-0701","journal-title":"Diabetes Care"},{"issue":"5","key":"6011_CR31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s11892-013-0407-7","volume":"13","author":"TJ Wilkin","year":"2013","unstructured":"Wilkin TJ (2013) Is autoimmunity or insulin resistance the primary driver of type 1 diabetes? Curr Diabetes Rep 13(5):651\u20136. https:\/\/doi.org\/10.1007\/s11892-013-0407-7","journal-title":"Curr Diabetes Rep"},{"issue":"12","key":"6011_CR32","doi-asserted-by":"publisher","first-page":"e4638","DOI":"10.1210\/clinem\/dgaa624","volume":"105","author":"PM P\u00f6ll\u00e4nen","year":"2020","unstructured":"P\u00f6ll\u00e4nen PM, Ryh\u00e4nen SJ, Toppari J et al (2020) Dynamics of islet autoantibodies during prospective follow-up from birth to age 15 years. J Clin Endocrinol Metab 105(12):e4638-4651. https:\/\/doi.org\/10.1210\/clinem\/dgaa624","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"6011_CR33","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1210\/jc.2018-00482","volume":"103","author":"TH Johannsen","year":"2018","unstructured":"Johannsen TH, Main KM, Ljubicic ML et al (2018) Sex differences in reproductive hormones during mini-puberty in infants with normal and disordered sex development. J Clin Endocrinol Metab 103(8):3028\u20133037. https:\/\/doi.org\/10.1210\/jc.2018-00482","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6011_CR34","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2337\/diabetes.50.2.470","volume":"50","author":"C Greenbaum","year":"2001","unstructured":"Greenbaum C, Cuthbertson D, Krischer J (2001) Type I diabetes manifested solely by 2-h oral glucose tolerance test criteria. Diabetes 50(2):470\u20136. https:\/\/doi.org\/10.2337\/diabetes.50.2.470","journal-title":"Diabetes"},{"issue":"6","key":"6011_CR35","doi-asserted-by":"publisher","first-page":"E1159","DOI":"10.1152\/ajpendo.00093.2002","volume":"283","author":"A Mari","year":"2002","unstructured":"Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283(6):E1159-66. https:\/\/doi.org\/10.1152\/ajpendo.00093.2002","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"6011_CR36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1530\/EJE-14-0911","volume":"173","author":"E Donga","year":"2015","unstructured":"Donga E, Dekkers O, Corssmit E, Romijn JA (2015) Insulin resistance in patients with type 1 diabetes assessed by glucose clamp studies: systematic review and meta-analysis. Eur J Endocrinol 173(1):101\u20139. https:\/\/doi.org\/10.1530\/EJE-14-0911","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"6011_CR37","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1210\/jc.2011-3172","volume":"97","author":"BC Bergman","year":"2012","unstructured":"Bergman BC, Howard D, Schauer IE et al (2012) Features of hepatic and skeletal muscle insulin resistance unique to type 1 diabetes. J Clin Endocrinol Metab 97(5):1663\u201372. https:\/\/doi.org\/10.1210\/jc.2011-3172","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"6011_CR38","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1172\/JCI119395","volume":"99","author":"GW Cline","year":"1997","unstructured":"Cline GW, Magnusson I, Rothman DL, Petersen KF, Laurent D, Shulman GI (1997) Mechanism of impaired insulin-stimulated muscle glucose metabolism in subjects with insulin-dependent diabetes mellitus. J Clin Invest 99(9):2219\u20132224. https:\/\/doi.org\/10.1172\/JCI119395","journal-title":"J Clin Invest"},{"issue":"9","key":"6011_CR39","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.2337\/dc20-0750","volume":"43","author":"F Piccinini","year":"2020","unstructured":"Piccinini F, Bergman R (2020) The measurement of insulin clearance. Diabetes Care 43(9):2296\u20132302. https:\/\/doi.org\/10.2337\/dc20-0750","journal-title":"Diabetes Care"},{"issue":"3","key":"6011_CR40","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1152\/physiol.00048.2018","volume":"34","author":"S Najjar","year":"2019","unstructured":"Najjar S, Perdomo G (2019) Hepatic insulin clearance: mechanism and physiology. Physiology (Bethesda, Md) 34(3):198\u2013215. https:\/\/doi.org\/10.1152\/physiol.00048.2018","journal-title":"Physiology (Bethesda, Md)"},{"issue":"1","key":"6011_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1172\/JCI109106","volume":"62","author":"O Faber","year":"1978","unstructured":"Faber O, Hagen C, Binder C et al (1978) Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Investig 62(1):197\u2013203. https:\/\/doi.org\/10.1172\/JCI109106","journal-title":"J Clin Investig"},{"issue":"1","key":"6011_CR42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/diabetes.53.1.250","volume":"53","author":"J Palmer","year":"2004","unstructured":"Palmer J, Fleming G, Greenbaum C et al (2004) C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21\u201322 October 2001. Diabetes 53(1):250\u201364. https:\/\/doi.org\/10.2337\/diabetes.53.1.250","journal-title":"Diabetes"},{"issue":"4","key":"6011_CR43","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2337\/diab.35.4.379","volume":"35","author":"K Polonsky","year":"1986","unstructured":"Polonsky K, Frank B, Pugh W et al (1986) The limitations to and valid use of C-peptide as a marker of the secretion of insulin. Diabetes 35(4):379\u201386. https:\/\/doi.org\/10.2337\/diab.35.4.379","journal-title":"Diabetes"},{"issue":"7","key":"6011_CR44","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/dme.12159","volume":"30","author":"A Jones","year":"2013","unstructured":"Jones A, Hattersley A (2013) The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabetic Med 30(7):803\u201317. https:\/\/doi.org\/10.1111\/dme.12159","journal-title":"Diabetic Med"},{"issue":"5","key":"6011_CR45","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.2337\/dc22-2236","volume":"46","author":"J Sosenko","year":"2023","unstructured":"Sosenko J, Cuthbertson D, Sims E et al (2023) Phenotypes associated with zones defined by area under the curve glucose and C-peptide in a population with islet autoantibodies. Diabetes Care 46(5):1098\u20131105. https:\/\/doi.org\/10.2337\/dc22-2236","journal-title":"Diabetes Care"},{"issue":"20","key":"6011_CR46","doi-asserted-by":"publisher","first-page":"e162123","DOI":"10.1172\/JCI162123","volume":"132","author":"K Warncke","year":"2022","unstructured":"Warncke K, Weiss A, Achenbach P et al (2022) Elevations in blood glucose before and after the appearance of islet autoantibodies in children. J Clin Invest 132(20):e162123. https:\/\/doi.org\/10.1172\/JCI162123","journal-title":"J Clin Invest"},{"issue":"10","key":"6011_CR47","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.2337\/dc22-0828","volume":"45","author":"K Vehik","year":"2022","unstructured":"Vehik K, Boulware D, Killian M et al (2022) Rising hemoglobin A1c in the nondiabetic range predicts progression of type 1 diabetes as well as oral glucose tolerance tests. Diabetes Care 45(10):2342\u20132349. https:\/\/doi.org\/10.2337\/dc22-0828","journal-title":"Diabetes Care"},{"issue":"8","key":"6011_CR48","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/pedi.13410","volume":"23","author":"R Besser","year":"2022","unstructured":"Besser R, Bell K, Couper J et al (2022) ISPAD Clinical Practice Consensus Guidelines 2022: stages of type 1 diabetes in children and adolescents. Pediatric Diabetes 23(8):1175\u20131187. https:\/\/doi.org\/10.1111\/pedi.13410","journal-title":"Pediatric Diabetes"},{"key":"6011_CR49","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-2849","author":"EK Sims","year":"2016","unstructured":"Sims EK, Chaudhry Z, Watkins R et al (2016) Elevations in the fasting serum proinsulin\u2013to\u2013C-peptide ratio precede the onset of type 1 diabetes. Diabetes Care. https:\/\/doi.org\/10.2337\/dc15-2849","journal-title":"Diabetes Care"},{"key":"6011_CR50","doi-asserted-by":"publisher","first-page":"100089","DOI":"10.1016\/j.jtauto.2021.100089","volume":"4","author":"TM Triolo","year":"2021","unstructured":"Triolo TM, Pyle L, Seligova S et al (2021) Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes. J Transl Autoimmun 4:100089. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100089","journal-title":"J Transl Autoimmun"},{"issue":"9","key":"6011_CR51","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1111\/j.1464-5491.2011.03272.x","volume":"28","author":"A Jones","year":"2011","unstructured":"Jones A, Besser R, McDonald TJ et al (2011) Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabetic Med J Br Diabetic Assoc 28(9):1034\u20138. https:\/\/doi.org\/10.1111\/j.1464-5491.2011.03272.x","journal-title":"Diabetic Med J Br Diabetic Assoc"},{"key":"6011_CR52","doi-asserted-by":"publisher","unstructured":"Oram R, Rawlingson A, Shields B et al (2013) Urine C-peptide creatinine ratio can be used to assess insulin resistance and insulin production in people without diabetes: an observational study. BMJ Open 3(12). https:\/\/doi.org\/10.1136\/bmjopen-2013-003193","DOI":"10.1136\/bmjopen-2013-003193"},{"issue":"2","key":"6011_CR53","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2337\/dc21-0944","volume":"45","author":"B Nathan","year":"2022","unstructured":"Nathan B, Redondo M, Ismail H et al (2022) Index60 identifies individuals at appreciable risk for stage 3 among an autoantibody-positive population with normal 2-hour glucose levels: implications for current staging criteria of type 1 diabetes. Diabetes Care 45(2):311\u2013318. https:\/\/doi.org\/10.2337\/dc21-0944","journal-title":"Diabetes Care"},{"issue":"4","key":"6011_CR54","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s00125-020-05365-4","volume":"64","author":"M Redondo","year":"2021","unstructured":"Redondo M, Nathan B, Jacobsen L et al (2021) Index60 as an additional diagnostic criterion for type 1 diabetes. Diabetologia 64(4):836\u2013844. https:\/\/doi.org\/10.1007\/s00125-020-05365-4","journal-title":"Diabetologia"},{"issue":"7","key":"6011_CR55","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2337\/db22-0097","volume":"71","author":"ALJ Carr","year":"2022","unstructured":"Carr ALJ, Inshaw JRJ, Flaxman CS et al (2022) Circulating C-peptide levels in living children and young people and pancreatic \u03b2-cell loss in pancreas donors across type 1 diabetes disease duration. Diabetes 71(7):1591\u20131596. https:\/\/doi.org\/10.2337\/db22-0097","journal-title":"Diabetes"},{"issue":"3","key":"6011_CR56","doi-asserted-by":"publisher","first-page":"476","DOI":"10.2337\/dc14-1952","volume":"38","author":"AK Davis","year":"2015","unstructured":"Davis AK, DuBose SN, Haller MJ et al (2015) Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care 38(3):476\u2013481. https:\/\/doi.org\/10.2337\/dc14-1952","journal-title":"Diabetes Care"},{"issue":"7","key":"6011_CR57","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S2213-8587(23)00123-7","volume":"11","author":"M Harsunen","year":"2023","unstructured":"Harsunen M, Haukka J, Harjutsalo V et al (2023) Residual insulin secretion in individuals with type 1 diabetes in Finland: longitudinal and cross-sectional analyses. Lancet Diabetes Endocrinol 11(7):465\u2013473. https:\/\/doi.org\/10.1016\/S2213-8587(23)00123-7","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"S1","key":"6011_CR58","first-page":"OPO57","volume":"24","author":"REJ Besser","year":"2022","unstructured":"Besser REJ, Long A, Owen K et al (2022) Transdermal capillary blood collection for C-peptide is a practical, acceptable and reliable alternative to venous sampling children nd adults with type 1 diabetes. Diabetes Technol Therapeut 24(S1):OPO57","journal-title":"Diabetes Technol Therapeut"},{"issue":"4","key":"6011_CR59","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2337\/dbi20-0054","volume":"71","author":"E Sims","year":"2022","unstructured":"Sims E, Besser R, Dayan C et al (2022) Screening for type 1 diabetes in the general population: a status report and perspective. Diabetes 71(4):610\u2013623. https:\/\/doi.org\/10.2337\/dbi20-0054","journal-title":"Diabetes"},{"issue":"2","key":"6011_CR60","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/pedi.12066","volume":"15","author":"H Elding Larsson","year":"2014","unstructured":"Elding Larsson H, Vehik K, Gesualdo P et al (2014) Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease. Pediatr Diabetes 15(2):118\u2013126. https:\/\/doi.org\/10.1111\/pedi.12066","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"6011_CR61","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1399-5448.2007.00269.x","volume":"8","author":"Teddy Study Group","year":"2007","unstructured":"Teddy Study Group (2007) The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 8(5):286\u2013298. https:\/\/doi.org\/10.1111\/j.1399-5448.2007.00269.x","journal-title":"Pediatr Diabetes"},{"issue":"2","key":"6011_CR62","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2337\/dc12-0836","volume":"36","author":"R Besser","year":"2013","unstructured":"Besser R, Shields B, Casas R, Hattersley A, Ludvigsson J (2013) Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 36(2):195\u2013201. https:\/\/doi.org\/10.2337\/dc12-0836","journal-title":"Diabetes Care"},{"key":"6011_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199635","author":"R Besser","year":"2022","unstructured":"Besser R, Ludvigsson J, Hindmarsh P, Cole P (2022) Exploring C-peptide loss in type 1 diabetes using growth curve analysis. PLOS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0199635","journal-title":"PLOS ONE"},{"issue":"5","key":"6011_CR64","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2337\/dc22-2200","volume":"46","author":"W Russell","year":"2023","unstructured":"Russell W, Bundy B, Anderson M et al (2023) Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial. Diabetes Care 46(5):1005\u20131013. https:\/\/doi.org\/10.2337\/dc22-2200","journal-title":"Diabetes Care"},{"issue":"11","key":"6011_CR65","doi-asserted-by":"publisher","first-page":"3766","DOI":"10.2337\/db13-0345","volume":"62","author":"K Herold","year":"2013","unstructured":"Herold K, Gitelman S, Ehlers M et al (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 62(11):3766\u201374. https:\/\/doi.org\/10.2337\/db13-0345","journal-title":"Diabetes"},{"issue":"9","key":"6011_CR66","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2337\/dc18-0494","volume":"41","author":"MJ Haller","year":"2018","unstructured":"Haller MJ, Schatz DA, Skyler JS et al (2018) Low-dose anti-thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA. Diabetes Care 41(9):1917\u20131925. https:\/\/doi.org\/10.2337\/dc18-0494","journal-title":"Diabetes Care"},{"issue":"6","key":"6011_CR67","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","volume":"54","author":"K Herold","year":"2005","unstructured":"Herold K, Gitelman S, Masharani U et al (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54(6):1763\u20139. https:\/\/doi.org\/10.2337\/diabetes.54.6.1763","journal-title":"Diabetes"},{"issue":"12","key":"6011_CR68","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1089\/dia.2020.0305","volume":"22","author":"LM Jacobsen","year":"2020","unstructured":"Jacobsen LM, Bundy BN, Greco MN et al (2020) Comparing beta cell preservation across clinical trials in recent-onset type 1 diabetes. Diabetes Technol Ther 22(12):948\u2013953. https:\/\/doi.org\/10.1089\/dia.2020.0305","journal-title":"Diabetes Technol Ther"},{"issue":"5","key":"6011_CR69","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.2337\/diabetes.52.5.1059","volume":"52","author":"CJ Greenbaum","year":"2003","unstructured":"Greenbaum CJ, Harrison LC (2003) Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes 52(5):1059\u20131065. https:\/\/doi.org\/10.2337\/diabetes.52.5.1059","journal-title":"Diabetes"},{"key":"6011_CR70","unstructured":"Martino M, Carr A, Perazzolo S, Galderisi A, Marcovecchio L, Dayan C (2023) Using disposition index to detect early impairment of beta cell function. 19th IDS Congress \u2013 Immunology of Diabetes Society (IDS), Paris, 23\u201326 May [Poster presentation]. Available from https:\/\/www.idsparis2023.com. Accessed 24 Aug 2023"},{"issue":"Suppl. 1","key":"6011_CR71","doi-asserted-by":"publisher","first-page":"731-P","DOI":"10.2337\/db23-731-P","volume":"72","author":"E Sims","year":"2023","unstructured":"Sims E, Russell W, Herold K, Sosenko J (2023) The effect of abatacept upon glucose and C-peptide endpoints at one year of treatment and on follow-up. Diabetes 72(Suppl. 1):731-P. https:\/\/doi.org\/10.2337\/db23-731-P","journal-title":"Diabetes"},{"issue":"3","key":"6011_CR72","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1210\/jcem-65-3-494","volume":"65","author":"I Zavaroni","year":"1987","unstructured":"Zavaroni I, Deferrari G, Lugari R et al (1987) Renal metabolism of C-peptide in man. J Clin Endocrinol Metab 65(3):494\u20138. https:\/\/doi.org\/10.1210\/jcem-65-3-494","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"6011_CR73","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/0026-0495(87)90044-8","volume":"36","author":"J Henriksen","year":"1987","unstructured":"Henriksen J, Tronier B, B\u00fclow J (1987) Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metab Clin Exp 36(5):463\u20138. https:\/\/doi.org\/10.1016\/0026-0495(87)90044-8","journal-title":"Metab Clin Exp"},{"issue":"1","key":"6011_CR74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1172\/JCI112308","volume":"77","author":"K Polonsky","year":"1986","unstructured":"Polonsky K, Licinio-Paixao J, Given B et al (1986) Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Investig 77(1):98\u2013105. https:\/\/doi.org\/10.1172\/JCI112308","journal-title":"J Clin Investig"},{"issue":"5","key":"6011_CR75","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1172\/JCI107697","volume":"53","author":"R Sherwin","year":"1974","unstructured":"Sherwin R, Kramer K, Tobin J et al (1974) A model of the kinetics of insulin in man. J Clin Investig 53(5):1481\u201392. https:\/\/doi.org\/10.1172\/JCI107697","journal-title":"J Clin Investig"},{"issue":"3","key":"6011_CR76","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1210\/jcem-51-3-520","volume":"51","author":"RP Eaton","year":"1980","unstructured":"Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J (1980) Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 51(3):520\u2013528. https:\/\/doi.org\/10.1210\/jcem-51-3-520","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"6011_CR77","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2337\/diab.41.3.368","volume":"41","author":"E Van Cauter","year":"1992","unstructured":"Van Cauter E, Mestrez F, Sturis J, Polonsky KS (1992) Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 41(3):368\u2013377. https:\/\/doi.org\/10.2337\/diab.41.3.368","journal-title":"Diabetes"},{"issue":"6","key":"6011_CR78","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1172\/JCI110398","volume":"68","author":"RN Bergman","year":"1981","unstructured":"Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68(6):1456\u20131467. https:\/\/doi.org\/10.1172\/JCI110398","journal-title":"J Clin Invest"},{"issue":"4","key":"6011_CR79","doi-asserted-by":"publisher","first-page":"E637","DOI":"10.1152\/ajpendo.00319.2003","volume":"287","author":"C Dalla Man","year":"2004","unstructured":"Dalla Man C, Caumo A, Basu R, Rizza R, Toffolo G, Cobelli C (2004) Minimal model estimation of glucose absorption and insulin sensitivity from oral test: validation with a tracer method. Am J Physiol Endocrinol Metab 287(4):E637-643. https:\/\/doi.org\/10.1152\/ajpendo.00319.2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"6011_CR80","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.2337\/diabetes.54.11.3265","volume":"54","author":"C Dalla Man","year":"2005","unstructured":"Dalla Man C, Campioni M, Polonsky K et al (2005) Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes 54(11):3265\u201373. https:\/\/doi.org\/10.2337\/diabetes.54.11.3265","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"6011_CR81","doi-asserted-by":"publisher","first-page":"S221","DOI":"10.2337\/diabetes.51.2007.s221","volume":"51","author":"A Mari","year":"2002","unstructured":"Mari A, Tura A, Gastaldelli A, Ferrannini E (2002) Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 51(Suppl 1):S221-6. https:\/\/doi.org\/10.2337\/diabetes.51.2007.s221","journal-title":"Diabetes"},{"issue":"1","key":"6011_CR82","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1210\/jc.2004-1133","volume":"90","author":"E Ferrannini","year":"2005","unstructured":"Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA (2005) Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 90(1):493\u2013500. https:\/\/doi.org\/10.1210\/jc.2004-1133","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"6011_CR83","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2337\/db13-1198","volume":"63","author":"C Cobelli","year":"2014","unstructured":"Cobelli C, Dalla Man C, Toffolo G, Basu R, Vella A, Rizza R (2014) The oral minimal model method. Diabetes 63(4):1203\u20131213. https:\/\/doi.org\/10.2337\/db13-1198","journal-title":"Diabetes"},{"issue":"2","key":"6011_CR84","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/oby.2008.496","volume":"17","author":"A Sunehag","year":"2009","unstructured":"Sunehag A, Dalla Man C, Toffolo G, Haymond M, Bier D, Cobelli C (2009) Beta-cell function and insulin sensitivity in adolescents from an OGTT. Obesity (Silver Spring, Md) 17(2):233\u20139. https:\/\/doi.org\/10.1038\/oby.2008.496","journal-title":"Obesity (Silver Spring, Md)"},{"issue":"3","key":"6011_CR85","doi-asserted-by":"publisher","first-page":"456","DOI":"10.2337\/dc08-1274","volume":"32","author":"AM Cali","year":"2009","unstructured":"Cali AM, Man CD, Cobelli C et al (2009) Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care 32(3):456\u2013461. https:\/\/doi.org\/10.2337\/dc08-1274","journal-title":"Diabetes Care"},{"issue":"6","key":"6011_CR86","doi-asserted-by":"publisher","first-page":"E1115","DOI":"10.1152\/ajpendo.00705.2009","volume":"298","author":"C Dalla Man","year":"2010","unstructured":"Dalla Man C, Micheletto F, Sathananthan A, Rizza RA, Vella A, Cobelli C (2010) A model of GLP-1 action on insulin secretion in nondiabetic subjects. Am J Physiol Endocrinol Metab 298(6):E1115-1121. https:\/\/doi.org\/10.1152\/ajpendo.00705.2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"6011_CR87","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00125-009-1647-6","volume":"53","author":"A Mari","year":"2010","unstructured":"Mari A, Tura A, Natali A et al (2010) Impaired beta cell glucose sensitivity rather than inadequate compensation for insulin resistance is the dominant defect in glucose intolerance. Diabetologia 53(4):749\u2013756. https:\/\/doi.org\/10.1007\/s00125-009-1647-6","journal-title":"Diabetologia"},{"issue":"8","key":"6011_CR88","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/s41591-020-0930-4","volume":"26","author":"LA Ferrat","year":"2020","unstructured":"Ferrat LA, Vehik K, Sharp SA et al (2020) A combined risk score enhances prediction of type 1 diabetes among susceptible children. Nat Med 26(8):1247\u20131255. https:\/\/doi.org\/10.1038\/s41591-020-0930-4","journal-title":"Nat Med"},{"issue":"1","key":"6011_CR89","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2337\/dc06-1615","volume":"30","author":"J Sosenko","year":"2007","unstructured":"Sosenko J, Palmer J, Greenbaum C et al (2007) Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 30(1):38\u201342. https:\/\/doi.org\/10.2337\/dc06-1615","journal-title":"Diabetes Care"},{"issue":"3","key":"6011_CR90","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2337\/dc07-1459","volume":"31","author":"J Sosenko","year":"2008","unstructured":"Sosenko J, Krischer J, Palmer J et al (2008) A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care 31(3):528\u201333. https:\/\/doi.org\/10.2337\/dc07-1459","journal-title":"Diabetes Care"},{"issue":"3","key":"6011_CR91","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/pedi.12609","volume":"19","author":"J Sosenko","year":"2018","unstructured":"Sosenko J, Geyer S, Skyler J et al (2018) The influence of body mass index and age on C-peptide at the diagnosis of type 1 diabetes in children who participated in the diabetes prevention trial-type 1. Pediatric Diabetes 19(3):403\u2013409. https:\/\/doi.org\/10.1111\/pedi.12609","journal-title":"Pediatric Diabetes"},{"issue":"4","key":"6011_CR92","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2337\/dc13-2359","volume":"37","author":"J Sosenko","year":"2014","unstructured":"Sosenko J, Skyler J, Mahon J et al (2014) Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes. Diabetes Care 37(4):979\u2013984. https:\/\/doi.org\/10.2337\/dc13-2359","journal-title":"Diabetes Care"},{"issue":"2","key":"6011_CR93","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2337\/dc14-1813","volume":"38","author":"J Sosenko","year":"2015","unstructured":"Sosenko J, Skyler J, DiMeglio L et al (2015) A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. Diabetes Care 38(2):271\u20136. https:\/\/doi.org\/10.2337\/dc14-1813","journal-title":"Diabetes Care"},{"issue":"7","key":"6011_CR94","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.2337\/dc13-2965","volume":"37","author":"A Steck","year":"2014","unstructured":"Steck A, Dong F, Taki I, Hoffman M, Klingensmith G, Rewers M (2014) Early hyperglycemia detected by continuous glucose monitoring in children at risk for type 1 diabetes. Diabetes Care 37(7):2031\u20133. https:\/\/doi.org\/10.2337\/dc13-2965","journal-title":"Diabetes Care"},{"issue":"3","key":"6011_CR95","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2337\/dc22-1297","volume":"46","author":"D Wilson","year":"2023","unstructured":"Wilson D, Pietropaolo S, Acevedo-Calado M et al (2023) CGM metrics identify dysglycemic states in participants from the TrialNet pathway to prevention study. Diabetes Care 46(3):526\u2013534. https:\/\/doi.org\/10.2337\/dc22-1297","journal-title":"Diabetes Care"},{"key":"6011_CR96","doi-asserted-by":"publisher","unstructured":"Ylescupidez A, Speake C, Pietropaolo SL et al (2023) OGTT metrics surpass continuous glucose monitoring data for T1D prediction in multiple-autoantibody-positive individuals. J Clin Endocrinol Metab dgad472. https:\/\/doi.org\/10.1210\/clinem\/dgad472","DOI":"10.1210\/clinem\/dgad472"}],"updated-by":[{"DOI":"10.1007\/s00125-024-06335-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000}}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-06011-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06011-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T03:02:01Z","timestamp":1732676521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-06011-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":96,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["6011"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-06011-5","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00125-024-06335-w","asserted-by":"object"}]},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"4 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00125-024-06335-w","URL":"https:\/\/doi.org\/10.1007\/s00125-024-06335-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AG\u2019s work is supported by the Juvenile Diabetes Research Foundation (JDRF SRA-2022-1186-S-B).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CD has lectured for or been involved as an advisor to the following companies: Novo Nordisk, Sanofi-Genzyme, Janssen, Servier, Lilly, AstraZeneca, Provention Bio, UCB, MSD, Vielo Bio, Avotres, Worg and Novartis. He also holds a patent jointly with Midatech and Provention Bio\/Sanofi. The other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"AG and ALJC drafted the initial manuscript. MM, PT, PS and CD contributed to the identification of literature, data interpretation and discussion. CD critically revised the manuscript and coordinated the working group. All authors approved the final version of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}